{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:56:27Z","timestamp":1787507787078,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J05332"],"award-info":[{"award-number":["2022J05332"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z20224ZD1081"],"award-info":[{"award-number":["3502Z20224ZD1081"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chromobox Homolog 1 (CBX1) plays a crucial role in the pathogenesis of numerous diseases, including the evolution and advancement of diverse cancers. The role of CBX1 in pan-cancer and its mechanism in hepatocellular carcinoma (HCC), however, remains to be further investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bioinformatics approaches were harnessed to scrutinize CBX1\u2019s expression profile, its association with tumor staging, and its potential impact on patient outcomes across various cancers. Single-cell RNA sequencing data facilitated the investigation of CBX1 expression patterns at the individual cell level. The CBX1 expression levels in HCC and adjacent non-tumor tissues were quantified through Real-Time Polymerase Chain Reaction (RT-PCR), Western Blotting (WB), and Immunohistochemical analyses. A tissue microarray was employed to explore the relationship between CBX1 levels, patient prognosis, and clinicopathological characteristics in HCC. Various in vitro assays\u2014including CCK-8, colony formation, Transwell invasion, and scratch tests\u2014were conducted to assess the proliferative and motility properties of HCC cells upon modulation of CBX1 expression. Moreover, the functional impact of CBX1 on HCC was further discerned through xenograft studies in nude mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CBX1 was found to be upregulated in most cancer forms, with heightened expression correlating with adverse patient prognoses. Within the context of HCC, elevated levels of CBX1 were consistently indicative of poorer clinical outcomes. Suppression of CBX1 through knockdown methodologies markedly diminished HCC cell proliferation, invasive capabilities, migratory activity, Epithelial\u2212mesenchymal transition (EMT) processes, and resistance to Tyrosine kinase inhibitors (TKIs). Contrastingly, CBX1 augmentation facilitated the opposite effects. Subsequent investigative efforts revealed CBX1 to be a promoter of EMT and a contributor to increased TKI resistance within HCC cells, mediated via the IGF-1R\/AKT\/SNAIL signaling axis. The oncogenic activities of CBX1 proved to be attenuable either by AKT pathway inhibition or by targeted silencing of IGF-1R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The broad overexpression of CBX1 in pan-cancer and specifically in HCC positions it as a putative oncogenic entity. It is implicated in forwarding HCC progression and exacerbating TKI resistance through its interaction with the IGF-1R\/AKT\/SNAIL signaling cascade.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12072-024-10696-0","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T14:02:33Z","timestamp":1716213753000},"page":"1499-1515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R\/AKT\/SNAIL signaling pathway"],"prefix":"10.1007","volume":"18","author":[{"given":"Su-Su","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Wu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Heng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"10696_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"10696_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.pharmthera.2017.02.010","volume":"173","author":"R Dutta","year":"2017","unstructured":"Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106\u2013117","journal-title":"Pharmacol Ther"},{"key":"10696_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864\u2013884","journal-title":"Nat Rev Clin Oncol"},{"key":"10696_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nsmb.2669","volume":"20","author":"L Di Croce","year":"2013","unstructured":"Di Croce L, Helin K. Transcriptional regulation by Polycomb group proteins. Nat Struct Mol Biol. 2013;20:1147\u20131155","journal-title":"Nat Struct Mol Biol"},{"key":"10696_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2010.12.021","volume":"41","author":"PD Kaufman","year":"2011","unstructured":"Kaufman PD. New partners for HP1 in transcriptional gene silencing. Mol Cell. 2011;41:1\u20132","journal-title":"Mol Cell"},{"key":"10696_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature722","volume":"416","author":"PR Nielsen","year":"2002","unstructured":"Nielsen PR, Nietlispach D, Mott HR, Callaghan J, Bannister A, Kouzarides T, et al. Structure of the HP1 chromodomain bound to histone H3 methylated at lysine 9. Nature. 2002;416:103\u2013107","journal-title":"Nature"},{"key":"10696_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13059-015-0760-8","volume":"16","author":"A Mattout","year":"2015","unstructured":"Mattout A, Aaronson Y, Sailaja BS, Raghu RE, Harikumar A, Mallm JP, et al. Heterochromatin Protein 1beta (HP1beta) has distinct functions and distinct nuclear distribution in pluripotent versus differentiated cells. Genome Biol. 2015;16:213","journal-title":"Genome Biol"},{"key":"10696_CR8","first-page":"154","volume":"74","author":"A Hu","year":"2019","unstructured":"Hu A, Zhang Y, Zhao X, Li J, Ying Y. CBX1 is a direct target of miR-205-5p and contributes to the progression of pituitary tumor. Pharmazie. 2019;74:154\u2013156","journal-title":"Pharmazie"},{"key":"10696_CR9","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.tranon.2018.07.002","volume":"11","author":"YF Yang","year":"2018","unstructured":"Yang YF, Pan YH, Tian QH, Wu DC, Su SG. CBX1 indicates poor outcomes and exerts oncogenic activity in hepatocellular carcinoma. Transl Oncol. 2018;11:1110\u20131118","journal-title":"Transl Oncol"},{"key":"10696_CR10","volume":"10","author":"YH Lee","year":"2015","unstructured":"Lee YH, Liu X, Qiu F, O\u2019Connor TR, Yen Y, Ann DK. HP1beta is a biomarker for breast cancer prognosis and PARP inhibitor therapy. PLoS ONE. 2015;10: e121207","journal-title":"PLoS ONE"},{"key":"10696_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.832354","volume":"10","author":"K Hu","year":"2022","unstructured":"Hu K, Yao L, Xu Z, Yan Y, Li J. Prognostic value and therapeutic potential of cbx family members in ovarian cancer. Front Cell Dev Biol. 2022;10: 832354","journal-title":"Front Cell Dev Biol"},{"key":"10696_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41467-019-14050-z","volume":"11","author":"B Losic","year":"2020","unstructured":"Losic B, Craig AJ, Villacorta-Martin C, Martins-Filho SN, Akers N, Chen X, et al. Intratumoral heterogeneity and clonal evolution in liver cancer. Nat Commun. 2020;11:291","journal-title":"Nat Commun"},{"key":"10696_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.789296","volume":"12","author":"S Zheng","year":"2021","unstructured":"Zheng S, Xie X, Guo X, Wu Y, Chen G, Chen X, et al. Identification of a pyroptosis-related gene signature for predicting overall survival and response to immunotherapy in hepatocellular carcinoma. Front Genet. 2021;12: 789296","journal-title":"Front Genet"},{"key":"10696_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/s-0030-1247133","volume":"30","author":"A Forner","year":"2010","unstructured":"Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61\u201374","journal-title":"Semin Liver Dis"},{"key":"10696_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.dld.2019.10.010","volume":"52","author":"JW Hu","year":"2020","unstructured":"Hu JW, Yang ZF, Li J, Hu B, Luo CB, Zhu K, et al. TGM3 promotes epithelial\u2212mesenchymal transition and hepatocellular carcinogenesis and predicts poor prognosis for patients after curative resection. Dig Liver Dis. 2020;52:668\u2013676","journal-title":"Dig Liver Dis"},{"key":"10696_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-019-0554-8","volume":"7","author":"CY Jing","year":"2019","unstructured":"Jing CY, Fu YP, Yi Y, Zhang MX, Zheng SS, Huang JL, et al. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. J Immunother Cancer. 2019;7:77","journal-title":"J Immunother Cancer"},{"key":"10696_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4103\/IJPM.IJPM_822_19","volume":"63","author":"JH Lee","year":"2020","unstructured":"Lee JH, Lee JH, Ahn BK, Paik SS, Kim H, Lee KH. Loss of ASXL1 expression is associated with lymph node metastasis in colorectal cancer. Indian J Pathol Microbiol. 2020;63:221\u2013225","journal-title":"Indian J Pathol Microbiol"},{"key":"10696_CR18","first-page":"1557","volume":"11","author":"JW Hu","year":"2021","unstructured":"Hu JW, Yin Y, Gao Y, Nie YY, Fu PY, Cai JB, et al. TM2D1 contributes the epithelial\u2212mesenchymal transition of hepatocellular carcinoma via modulating AKT\/beta-catenin axis. Am J Cancer Res. 2021;11:1557\u20131571","journal-title":"Am J Cancer Res"},{"key":"10696_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110908","volume":"112","author":"WF Liu","year":"2023","unstructured":"Liu WF, Zhang QW, Quan B, Zhang F, Li M, Lu SX, et al. Gas7 attenuates hepatocellular carcinoma progression and chemoresistance through the PI3K\/Akt signaling pathway. Cell Signal. 2023;112: 110908","journal-title":"Cell Signal"},{"key":"10696_CR20","doi-asserted-by":"publisher","first-page":"1118377","DOI":"10.3389\/fmolb.2023.1118377","volume":"10","author":"SS Zheng","year":"2023","unstructured":"Zheng SS, Wu YF, Zhang BH, Huang C, Xue TC. A novel myeloid cell marker genes related signature can indicate immune infiltration and predict prognosis of hepatocellular carcinoma: integrated analysis of bulk and single-cell RNA sequencing. Front Mol Biosci. 2023;10:1118377","journal-title":"Front Mol Biosci"},{"key":"10696_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202205091","volume":"9","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Huang S, Tan X, Long L, He Q, Liang X, et al. N(6) -methyladenosine-modified CBX1 regulates nasopharyngeal carcinoma progression through heterochromatin formation and STAT1 activation. Adv Sci (Weinh). 2022;9: e2205091","journal-title":"Adv Sci (Weinh)"},{"key":"10696_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1530\/JME-13-0024","volume":"50","author":"M Itsumi","year":"2013","unstructured":"Itsumi M, Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Tatsugami K, et al. Human heterochromatin protein 1 isoforms regulate androgen receptor signaling in prostate cancer. J Mol Endocrinol. 2013;50:401\u2013409","journal-title":"J Mol Endocrinol"},{"key":"10696_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821\u2013829","journal-title":"J Hepatol"},{"key":"10696_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S2468-1253(21)00110-2","volume":"6","author":"A Vogel","year":"2021","unstructured":"Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:649\u2013658","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10696_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","volume":"22","author":"PR Galle","year":"2021","unstructured":"Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:991\u20131001","journal-title":"Lancet Oncol"},{"key":"10696_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133\u20131146","journal-title":"Lancet"},{"key":"10696_CR27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jceh.2019.07.012","volume":"9","author":"I Doycheva","year":"2019","unstructured":"Doycheva I, Thuluvath PJ. Systemic therapy for advanced hepatocellular carcinoma: an update of a rapidly evolving field. J Clin Exp Hepatol. 2019;9:588\u2013596","journal-title":"J Clin Exp Hepatol"},{"key":"10696_CR28","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u20131173","journal-title":"Lancet"},{"key":"10696_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semcancer.2023.10.001","volume":"97","author":"M Saitoh","year":"2023","unstructured":"Saitoh M. Transcriptional regulation of EMT transcription factors in cancer. Semin Cancer Biol. 2023;97:21\u201329","journal-title":"Semin Cancer Biol"},{"key":"10696_CR30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2174\/1568009617666170427104356","volume":"17","author":"N Mir","year":"2017","unstructured":"Mir N, Jayachandran A, Dhungel B, Shrestha R, Steel JC. Epithelial-to-mesenchymal transition: a mediator of sorafenib resistance in advanced hepatocellular carcinoma. Curr Cancer Drug Targets. 2017;17:698\u2013706","journal-title":"Curr Cancer Drug Targets"},{"key":"10696_CR31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","volume":"72","author":"S Faivre","year":"2020","unstructured":"Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol. 2020;72:342\u2013352","journal-title":"J Hepatol"},{"key":"10696_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cac2.12414","volume":"43","author":"JW Eun","year":"2023","unstructured":"Eun JW, Yoon JH, Ahn HR, Kim S, Kim YB, Lim SB, et al. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun (Lond). 2023;43:455\u2013479","journal-title":"Cancer Commun (Lond)"},{"key":"10696_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s10147-020-01832-5","volume":"26","author":"G Tan","year":"2021","unstructured":"Tan G, Xie B, Yu N, Huang J, Zhang B, Lin F, et al. TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway. Int J Clin Oncol. 2021;26:532\u2013542","journal-title":"Int J Clin Oncol"},{"key":"10696_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12885-023-10561-7","volume":"23","author":"W Cai","year":"2023","unstructured":"Cai W, Ma Y, Song L, Cao N, Gao J, Zhou S, et al. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K \/ akt and RAS \/ raf \/ ERK signaling pathways. BMC Cancer. 2023;23:87","journal-title":"BMC Cancer"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10696-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10696-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10696-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T15:07:39Z","timestamp":1728400059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10696-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10696"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10696-0","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"17 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Su-Su Zheng, Jing-Fang Wu, Wei-Xun Wu, Jin-Wu Hu, Dai Zhang, Cheng Huang, Bo-Heng Zhang declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Zhongshan Hospital, Fudan University, and informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}